Treatment-Resistant Depression (TRD):

Treatment-Resistant Depression (TRD) is defined as a major depressive disorder that fails to respond to at least two adequate trials of antidepressants from different pharmacologic classes.

Epidemiology:

TRD affects about 20–30% of individuals with major depressive disorder, contributing to higher rates of disability and healthcare costs.

Pathophysiology:

Key mechanisms involve neurotransmitter dysregulation (serotonin, dopamine, norepinephrine), glutamate/GABA imbalance, HPA axis dysfunction, inflammation, and impaired neuroplasticity.

Diagnosis:

Diagnosis of TRD requires failure to respond to two or more adequate antidepressant trials. Tools like the Maudsley Staging Method and Thase-Rush Staging are used.

Treatment Approaches

These include pharmacological augmentation (e.g., atypical antipsychotics, lithium), novel therapies (e.g., ketamine, psilocybin), brain stimulation (ECT, rTMS), and psychotherapies (CBT, MBCT).

Psilocybin in TRD

Psilocybin is a classic serotonergic psychedelic compound that primarily acts as a partial agonist at the 5-HT2A receptor. This receptor is densely expressed in cortical areas related to perception, cognition, and emotion. Psilocybin is metabolized into psilocin, which crosses the blood-brain barrier and binds to serotonin receptors, initiating a cascade of neurochemical and neuroplastic changes.

Mechanisms of Action:

5-HT2A Agonism: Leads to increased excitability in layer V pyramidal neurons, facilitating enhanced cross-talk between brain regions.
Neuroplasticity: Psilocybin has been shown to promote dendritic growth and synaptogenesis in both preclinical and human models. Ly et al. (2018) demonstrated increased spine density in rodents after a single psilocybin dose.
Reduction in DMN Connectivity: Carhart-Harris et al. (2014) observed decreased connectivity in the Default Mode Network, believed to underpin rigid self-referential thinking and rumination.
Glutamatergic Transmission: Enhanced glutamate signaling in the prefrontal cortex has been observed, potentially reversing the hypofrontality seen in TRD.
Emotional Catharsis: Increased amygdala reactivity allows suppressed emotions to be accessed and processed in a safe therapeutic setting (Roseman et al., 2018).

Clinical Evidence:

Numerous randomized controlled trials and open-label studies have reported psilocybin’s efficacy in TRD:

Carhart-Harris et al. (2021) - NEJM: 59 participants with MDD were randomized to receive either two psilocybin sessions (25 mg) or daily escitalopram. The psilocybin group showed greater reductions in depression scores on QIDS-SR-16.
Davis et al. (2020) - JAMA Psychiatry: Two psilocybin sessions in 24 patients led to >70% response rate and 54% remission at four weeks.
Griffiths et al. (2016) - Journal of Psychopharmacology: In patients with life-threatening cancer and anxiety/depression, psilocybin produced sustained reductions in symptoms for over six months.

Safety & Regulation:

Psilocybin is non-addictive, with minimal physiological toxicity. Side effects include transient anxiety, nausea, and increased blood pressure during onset. It is classified as a Schedule I substance in the U.S., though the FDA has granted Breakthrough Therapy Designation for psilocybin in TRD (to COMPASS Pathways and Usona Institute).

Psilocybin is a naturally occurring psychedelic compound found in over 180 species of mushrooms, primarily of the genus Psilocybe. It is a prodrug, rapidly converted in the body to psilocin, which acts as a partial agonist at the 5-HT2A receptor, a key receptor involved in mood regulation, perception, and cognition.

In the context of Treatment-Resistant Depression, psilocybin demonstrates several mechanisms of action:

Neuroplasticity: Psilocybin increases expression of Brain-Derived Neurotrophic Factor (BDNF), promoting the growth and repair of neurons. Animal studies show increased dendritic spine formation and synaptogenesis.
Default Mode Network (DMN) Modulation: Psilocybin disrupts hyperconnectivity in the DMN, which is often associated with rumination and self-referential thinking in depression.
Emotional Release: Functional MRI studies reveal increased amygdala responsiveness to emotional stimuli, allowing patients to better process repressed trauma and emotional content.
Glutamate Signaling: Psilocybin indirectly modulates glutamatergic transmission, increasing cortical excitability and potentially reversing the synaptic deficits found in TRD.

Clinical trials have shown that a single dose of psilocybin (25 mg) administered in a supportive setting can lead to significant reductions in depression scores. In a 2021 randomized controlled trial published in the New England Journal of Medicine, psilocybin showed comparable efficacy to escitalopram, a standard SSRI, with faster onset and sustained improvement.

Safety profiles indicate transient increases in blood pressure and mild-to-moderate adverse effects like anxiety during onset, but no long-term toxicity or addiction potential. Psilocybin is currently designated as a Breakthrough Therapy for TRD by the FDA.

Research Highlights:

Recent trials highlight the promise of psilocybin, ketamine, and anti-inflammatory agents. Biomarkers like BDNF, IL-6, and CRP are under investigation.

Prognosis & Risk:

Poor prognosis correlates with early onset, long illness duration, comorbid conditions, and low support. TRD significantly elevates suicide risk.

References:

Rush AJ et al. (2006). Am J Psychiatry.
Duman RS, Aghajanian GK (2012). Science.
Carhart-Harris RL et al. (2021). NEJM.
McIntyre RS et al. (2021). J Clin Psychiatry.
Strawbridge R et al. (2019). Int J Neuropsychopharmacol.

Thanks for reading and sharing! Call or text anytime.

800 W. 8th Ave #110 Denver Colorado - (303) 591-1960 - Join our email list!